Century Therapeutics’ (IPSC) “Buy” Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report released on Wednesday morning,Benzinga reports.

Several other research firms have also recently commented on IPSC. Piper Sandler reduced their target price on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday. Finally, Chardan Capital decreased their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Century Therapeutics has an average rating of “Buy” and an average price target of $10.00.

Century Therapeutics Trading Down 1.1 %

IPSC opened at $0.90 on Wednesday. Century Therapeutics has a twelve month low of $0.86 and a twelve month high of $5.51. The firm has a market cap of $76.53 million, a price-to-earnings ratio of -0.49 and a beta of 1.76. The company has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.55.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The company had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.47 million. During the same period last year, the firm earned ($0.55) earnings per share. On average, analysts forecast that Century Therapeutics will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Century Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Century Therapeutics in the 3rd quarter worth about $27,000. Rhumbline Advisers lifted its holdings in Century Therapeutics by 56.0% in the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares during the last quarter. Barclays PLC boosted its stake in Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Century Therapeutics by 257.6% during the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after purchasing an additional 51,664 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares during the period. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.